The estrogen receptors a (ERa) and b (ERb) are located in the nucleus and bind to estrogen to initiate transcription of estrogen-responsive genes. In a variety of tumor cells, ERb has been shown to be a tumor suppressor. In particular, ERb has anti-proliferative effects in osteosarcoma cells. Additionally, ERb has been proven to regulate the apoptosis-related molecules IAP, BAX, caspase-3, and PARP, and to act on the NF-jB/BCL-2 pathway to induce apoptosis in tumors. Moreover, ERb can regulate the expression of the autophagy associated markers LC3-I/LC-3II and p62 and induce autophagy in tumors by inhibiting the PI3K/AKT/mTOR pathway and activating the AMPK pathway. Here, we review the molecular mechanisms by which ERb induces apoptosis and autophagy in a variety of tumors to further delineate more specific molecular mechanisms underlying osteosarcoma tumorigenesis and pathogenesis. Considering the broad involvement of ERb in apoptosis, autophagy, and their interaction, it is plausible that the critical role of ERb in inhibiting the proliferation and metastasis of osteosarcoma cells is closely related to its regulation of apoptosis and autophagy.
Introduction
Estrogen receptors are ligand-dependent receptors that are located in the nucleus and composed of two subtypes: estrogen receptor a (ERa) and estrogen receptor b (ERb). These two subtypes have similar structures, and both consist of a DNA binding domain, a ligand binding domain, a ligand-independent transcriptional activation region (AF-1) at the N-terminus, and a ligand-dependent transcriptional activation region at the C-terminus (AF-2). 1 Both estrogen receptor subtypes can initiate transcription of estrogen-responsive genes either in the form of a homodimer or a heterodimer after binding to estrogen. While the transcriptional activation function of AF-1 from ERb is weaker compared with ERa, AF-2 from ERb has comparable function to ERa. 2 Additionally, ERb contains a repressor domain at the N-terminus. When hormones are at sub-saturated levels, ERb can inhibit the transcriptional activity of ERa, thereby reducing the sensitivity of cells to estrogen. 3 ERb has been proven to be a tumor suppressor in many tumor types. In prostate cancer cells, ERb promotes apoptosis and inhibits cell proliferation, invasion, metastasis, and epithelial-mesenchymal transition (EMT). 4, 5 In ovarian cancer cells, ERb inhibits cell growth and potentiates the antitumor activity of chemotherapy drugs, including cisplatin and taxol. 6, 7 ERb overexpression inhibits the growth of ERa-expressing breast cancer cells and prevents the production of estrogen-induced breast cancer xenografts in nude mice. 8, 9 ERb can influence downstream cell cycle progression by initiating the transcription of cell cycle-related target genes. 10, 11 For example, in breast cancer cells that endogenously express ERa, ERb overexpression prevents proliferation by inhibiting cyclin D1 expression and activating p21 and p27 expression to induce G2 cell cycle arrest. 8 In malignant pleural mesothelioma cells, ERb functions as a tumor suppressor and its activation sensitizes tumor cells to cisplatin. 12 Moreover, ERb expression has been revealed to be regulated by the AKT1/SIRT1/FOXM1 axis, while activated ERb can inhibit AKT1 signaling, thus demonstrating an inhibitory feedback loop for ERb. 13 ERa and ERb have been identified in both healthy human bone cells and osteosarcoma cells, [14] [15] [16] and ERa and ERb are stably expressed at a 1:4 ratio in the osteosarcoma cell line U2-OS. 17 However, in the osteosarcoma cell line 143B, which has high metastatic ability, only ERb expression was detected. 18 In recent years, estrogen and its nuclear receptors have attracted widespread attention as potential targets for treating osteosarcoma. In the highly metastatic osteosarcoma cell line 143B, inhibition of cell proliferation by the 17-e-diol derivative 2-ME was more prominent when higher doses were used, and the estrogen inhibitor fulvestrant inhibited cell growth at high concentrations. Intriguingly, fulvestrant down-regulated ERb expression, while 2-ME enhanced ERb expression. 18 Therefore, the specific molecular mechanisms by which ERb inhibits tumorigenesis in osteosarcoma cells are unclear. Recently, we reported that ERb exerts antitumor effects in osteosarcoma U2-OS cells that are reliant on the roles of ERb in regulating integrin, IAP, and the Nuclear factor-jB (NF-kB)/BCL-2 and phosphoinositide 3-kinase (PI3K)/AKT (protein kinase B) signaling pathways. 19 Here, we review the molecular mechanisms by which ERb induces apoptosis and autophagy in a variety of tumors to further delineate more specific molecular mechanisms underlying osteosarcoma tumorigenesis and pathogenesis, as this might help pave the way for targeting ERb to treat osteosarcoma and reduce mortality rates.
Overview of the molecular mechanisms by which ERb inhibits tumor cell proliferation and metastasis
Generally, cell death is predominantly induced by apoptosis and autophagy, but other processes like necrosis, aging, and karyokinesis also result in cell death. Studies have confirmed that ERb plays a role in inducing apoptosis in various tissues. In estrogen-treated mouse mammary cells, ERa promotes cell proliferation, whereas ERb inhibits cell growth and induces apoptosis. 20 In human prostate cancer cells, ERb induces apoptosis by enhancing the transcription of FOXO3a, which in turn elevates p53 upregulated modulator of apoptosis (PUMA) expression. 21 In nude mice, the ERb activator diosgenin can inhibit the growth of prostate cancer xenografts. 22 Autophagy is another mechanism by which cell death occurs. Autophagy is usually activated in cells under stress conditions. 23 During autophagy, redundant proteins and/or organelles that do not affect survival are phagocytosed in double-or multi-layered vesicles to form autophagosomes. Subsequently, lysosomes are fused with autophagosomes and release proteases to degrade the contents of the autophagosomes. 24 Autophagy is a double-edged sword, such that it can be both beneficial and detrimental. Under normal environmental conditions, healthy cells maintain basal cellular activities and prevent malignant transformation through autophagy. In contrast, during stress, such as hypoxia or starvation, tumor cells can be controlled by autophagy pathways and are more likely to survive than healthy cells. 25 This also applies to conditions related to cancer chemotherapy, in which tumor cells can evade anticancer drugs through autophagy and become drug resistant. 25 It has been reported that autophagy suppresses tumors in most breast, uterine, and prostate cancers. 26 Studies have shown that estrogen receptors also induce autophagy. For instance, in hormone-resistant breast cancer cells, ERb agonists reduce Bcl-2 expression and activate autophagy. 27 In Hodgkin's lymphoma, ERb activation induces autophagy, inhibits proliferation, and causes cell cycle arrest. 28 Recently, complex interactions between autophagy and apoptosis have been uncovered. Multiple stresses activate both autophagy and apoptosis, which share multiple upstream and downstream regulatory molecules, and thus can be mutually transformed. 29 In osteosarcoma cells, lignin DPT can simultaneously induce apoptosis and autophagy. DPT induces autophagy by inhibiting activation of the PI3K/AKT/ mammalian target of rapamycin (mTOR) pathway and blocking tumor cell apoptosis. In contrast, the autophagy inhibitor 3methyladeine (3-MA) reverses this effect and promotes apoptosis. 30 An in-depth study of the interactions between autophagy and apoptosis will reveal mechanisms underlying the pathogenesis of various diseases and tumorigenesis of various cancers, shedding new light on methods to treat these cancers and other diseases.
Molecular mechanisms of ERb-induced apoptosis in tumor cells

ERb induces apoptosis by regulating expression of the anti-apoptotic IAP proteins
The anti-apoptotic proteins inhibitors of apoptosis proteins (IAP) are a class of functional proteins that bind and inhibit caspases to prevent cell death. 31 A mixture of the anticancer drugs mistletoe and triterpene inhibits IAP expression in osteosarcoma cells and synergistically induces apoptosis. 32 Decreased expression of the IAP family protein X-linked inhibitor of apoptosis (X-IAP) inhibits proliferation and induces apoptosis in osteosarcoma cells. 33 Microarray analysis showed that ERb regulates expression of the IAP family protein SURVIVIN in human breast cancer cells. 10 Moreover, ERb regulates expression of the IAP family protein cIAP2 in epithelial colorectal cancer cells. 34 ERb induces apoptosis by regulating the NF-jB/BCL-2 pathway NF-jB is a pro-inflammatory factor that is involved in a variety of cellular processes including proliferation, differentiation, apoptosis, and inflammation. 35 It has been reported that estrogen receptors are associated with NF-jB signaling pathways in tumor cells. In bladder cancer cells, ERb levels are negatively correlated with nuclear p65 levels. 36 NF-jB directly regulates transcription of the anti-apoptotic factor BCL-2; thus, the NF-jB/BCL-2 pathway is thought to play an important role in tumorigenesis and apoptosis. 37 Immunohistochemical analysis showed that the occurrence of endometriosisassociated tumors correlated with high BCL-2 expression and decreased expression of estrogen receptors. 38 In hormoneresistant breast cancer cells, ERb agonists reduce BCL-2 expression and activate autophagy. 27 
ERb regulates expression of proapoptotic factor BAX
The pro-apoptotic protein BAX is a member of the BCL-2 gene family and forms a heterodimer with BCL-2 to function as a pro-apoptotic factor. 39 After opening the mitochondrial voltagedependent anion channel, BAX releases cytochrome C to force cells to enter the apoptotic program. 40 In clinical studies of non-small cell lung cancer, high ERb2 and BAX expression were positively correlated with patient survival. 41 Moreover, artificial introduction of ERb into prostate cancer cells that do not express estrogen receptors can upregulate BAX expression and induce apoptosis. 42 
ERb regulates caspase-3 expression
Caspase-3 is a key regulator of apoptosis that specifically catalyzes the cleavage of many important cellular proteins. 43, 44 A biomarker of apoptosis, caspase-3 is essential for the chromatin condensation and DNA fragmentation during apoptosis. 44 The phytoestrogens genistein and apigenin inhibit proliferation of prostate cancer and breast cancer cells by activating caspase-3 and promoting apoptosis. Luciferase reporter assays and knockdown experiments have indicated that apigenin specifically activates caspase-3 mRNA transcription through ERb, while genistein activates caspase-3 transcription through both ERa and ERb. 45 In prostate cancer cells, diosgenin induces apoptosis by activating ERb to regulate caspase-3 expression. 22 Artificial expression of ERb in prostate cancer cells that do not express nuclear estrogen receptors promote the expression of caspase-3 and induce apoptosis. 42 In colon cancer cells, nitric oxide inhibits ERb activity and down-regulates caspase-3 expression, preventing estrogeninduced apoptosis. 46 
ERb regulates PARP expression
The primary role of Poly (ADP-ribose) polymerase 1 (PARP) is to detect breaks in single-stranded DNA and induce stress responses to repair DNA in cells. 47 PARP uses nicotinamide adenine dinucleotide (NAD) as a donor to attach ADP-ribose to various nuclear proteins. 48 As PARP is activated by binding to the ends of DNA strands or strand breaks, it is believed that PARP causes cell death by depleting NAD and ATP in cells. 49 During apoptosis, caspase-3 is primarily responsible for cleaving PARP at a highly evolutionarily conserved cleavage site, indicating that PARP cleavage plays an important role in apoptosis. 50 In breast cancer cells that express estrogen receptors, isoflavones induce apoptosis by increasing ERb expression to initiate PARP cleavage. 51 Furthermore, artificial expression of ERb in estrogen receptor-deficient prostate cancer cells promote PARP expression and accelerate apoptosis. 42 
Molecular mechanisms of ERb-induced autophagy in tumor cells
ERb induces autophagy by regulating LC3-I/II expression
LC3 is a microtubule-associated protein that is constitutively expressed in mammalian tissues. During autophagy, LC3-I, the cytosolic form of LC3, binds to phosphatidylethanolamine to form LC3-II, which is transported to autophagosome membranes. 52 When autophagosomes are fused to lysosomes to form autophagosomes, LC3-II in autophagosomes is degraded. 52 Thus, the relative ratio of LC3-I/LC3-II expression can be used to monitor autophagy progression. 53 In Hodgkin's lymphoma cells that are treated with lysosomal protease inhibitors, the ERb agonist DPN enhances LC3-II expression. This suggests that ERb induces autophagy to promote autophagosome formation and causes LC3-II formation even when the lysis function of lysosomes is inhibited. 28 
ERb regulates p62 expression
P62 is a cytoskeletal protein with a ubiquitin-binding domain that has been found to co-localize with ubiquitinated protein aggregates in many neuropathic and liver diseases. 54 LC3 and the GABA type A receptor-associated protein (GABARAP) family proteins recognize and bind to specific sequences in p62. During autophagy, p62 recognizes toxic cellular waste, which is engulfed by autophagosomes and degraded by lysosomes. 55 When autophagy is inhibited, p62 and ubiquitinated protein aggregates in the cell accumulate, and when autophagy is activated, p62 levels continuously decrease. 54, 55 Thus, p62 is used as a marker to study autophagic flow in cells. In choriocarcinoma cells, reactive oxygen species regulate the transition of methotrexate-induced apoptosis to autophagy through the JNK/p62 pathway, which results in the resistance of choriocarcinoma to methotrexate. 56 ERa overexpression in breast cancer cells with endogenous ERa expression has been reported to enhance p62 expression and activate autophagy. 57 However, the role of ERb and p62 in autophagy has not been reported in the literature so far, and more extensive investigations are needed to explore their possible link.
ERb induces autophagy by inhibiting the PI3K/AKT/mTOR pathway
The protein kinase mTOR is the primary regulator of autophagy. mTOR receives signals from various pathways, especially those related to the cellular energy state and the initiation or arrest of protein synthesis. 58 mTOR forms two complexes, mammalian target of rapamycin complex 1 (mTORC1) and complex 2 (mTORC2), which have different protein compositions. 59 The PI3K/AKT signaling pathway is a major upstream regulator of mTORC1 and is normally activated by cell growth factors to promote cell survival and inhibit apoptosis in various cell types. 60, 61 mTORC2 is involved in AKT phosphorylation. 59, 60 Activation of AKT can lead to the phosphorylation of BAD, 62 inactivation of caspase-9, 63 inhibition of the nuclear transfer of the transcription factor FKHRL1 (which regulates the transcription of cell death genes), 64 and enhancement of mTOR activity, 65 thereby inhibiting apoptosis. In the case of starvation or environmental stress, inhibition of mTOR activity leads to the activation of the autophagy-activated kinase ULK1 and autophagosome formation. 66 Additionally, immunosuppressive drugs and rapamycin, which inhibits mTOR, initiates autophagy and autophagosome formation. 66 Overall, activation of the PI3K/AKT/mTOR pathway increases cell viability and prevents cell death caused by excessive autophagy, while inhibition of mTORC1 activity induces autophagy to clean up toxic waste in cells. Meanwhile, mTORC2 regulates AKT activity to increase cell viability. 67 The PI3K/ AKT/mTOR pathway is associated with the estrogen receptor signaling pathway, and the downstream target gene p70S6K of mTORC1 negatively regulates AKT and activates estrogen receptors through phosphorylation. Moreover, in breast cancer cells, p70S6K overexpression has been reported to activate estrogen receptors. 68, 69 In ERa-positive breast cancer, arctigenin, a member of the Asteraceae family, has been shown to inhibit mTOR pathway activation, resulting in decreased ER expression and increased autophagic cell death. 69 Additionally, arctigenin has also been reported to function as a selective agonist of ERb to restrict mTORC1 activation in T cell lines; 70 thus, it is plausible that agonist-mediated activation of ERb can inhibit mTORC1 to induce autophagic cell death in tumors.
ERb induces autophagy by activating the AMPK pathway
In mammalian cells, the protein kinase AMPK senses ATP levels, thereby sensing the cellular energy status. 24, 71 When the ATP/ AMP ratio in cells decreases, AMPK is activated by the upstream protein kinase LKB1. 71 Activated AMPK phosphorylates and activates the TSC1/2 complex, which inhibits mTOR activity via Rheb, thereby initiating autophagy. 72 Autophagy leads to the reuse of nutrients in cells, which enhances ATP production and restores a normal ATP/AMP ratio. 71 Conversely, the LKB1-AMPK pathway leads to the phosphorylation and activation of the cyclin-dependent kinase inhibitor p27kip1. 73 Under conditions of growth factor withdrawal and nutrient deprival, p27kip1 responds to stress by inducing autophagy to prevent cells from entering the apoptotic process, allowing survival. 73 Several studies have shown that estradiol activates AMPK by enhancing phosphorylation of the alpha catalytic subunit (AMPKa) of AMPK. [74] [75] [76] In breast cancer and cardiomyocytes, ERa directly binds to AMPKa, and both ERa and ERb interact with LKB1, which is upstream of AMPK. 77 In castrated male mice, testosterone activates the expression of the autophagosomeforming marker ALP and induces TSC2 expression to activate AMPKa, while ERa is downregulated and ERb expression is enhanced in muscle cells. 78 These findings demonstrate that ERb induces autophagy by activating the AMPK pathway. 
Conclusions
ERb exhibits antitumor effects in different tumor types. ERb regulates the apoptosisrelated proteins IAP, BAX, caspase-3, and PARP, and influences NF-jB/BCL-2 signaling to induce apoptosis (Figure 1) . ERb is also involved in the induction of autophagy by inhibiting the PI3K/AKT/ mTOR pathway and activating the AMPK pathway ( Figure 2 ). Our previous report revealed that ERb exerts antitumor effects in osteosarcoma U2-OS cells through the NF-jB/BCL-2 and PI3K/ AKT/mTOR pathways. 19 Considering the broad involvement of ERb in the linked processes of apoptosis, autophagy, it is plausible that the critical role of ERb in inhibiting the proliferation and metastasis of osteosarcoma cells is closely related to its regulation of apoptosis and autophagy.
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